The development of cysts, which are fluid-filled sacs, in the kidneys, hindering with their ability to filter waste products from the blood, is termed as polycystic kidney disease (PKD). These cysts may grow bigger and enlarge the kidneys, eventually resulting in their failure. Cyst formation may also be observed in other organs, such as the liver. The two major forms of this disease are autosomal dominant (AD) PKD and autosomal recessive (AR) PKD.
Even though cysts are present in kidneys of people with ADPKD since birth or childhood, the disease starts displaying symptoms in adulthood. It can be further divided into type 1 and 2 depending on the affected genes. The signs and symptoms associated with ARPKD appear at birth or early infancy, and even though this form of PKD is rare, it often proves to be lethal early in life.
One of the drivers for the PKD therapeutics pipeline is the technical advancements in the drug manufacturing process that have enabled pharmaceutical companies to try innovative ways to come up with improved drugs. These advancements have led to the development of drugs as single-agent or combination therapies. For instance, Mannin research Inc. is developing a new class of drugs for the treatment of various diseases, such as pediatric glaucoma, open angle glaucoma, inflammation, and cystic kidney disease.
The PKD therapeutics pipeline comprised about 16 candidates in November 2017. Tolvaptan, a drug in the pipeline being developed by Otsuka Pharmaceutical Co. Ltd., was in the filed stage of the development process in 2017 in the U.S. Obtained from a synthetic source, it is a small molecule being developed to be administered orally. This drug is a selective vasopressin V2 receptor antagonist that works by blocking vasopressin at the V2 receptor. It has been effective in decreasing cyst cell proliferation and fluid secretion, thereby reducing cyst development.
Pre-Purchase Inquiry at: https://www.pharmaproff.com/enquiry/1245
This shows that the pipeline is constantly growing, which is positive news for people suffering from PKD.
0 Comments